Please Wait
Applying Filters...
menu
    • menu
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    HealthTech BioActives, leading globally in Flavonoids and Vitamin B12 Derivatives.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Menu

    Obefazimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abivax To Present Late-Breaking Abtect Phase 3 Data At 2025 UEG
    Abivax To Present Late-Breaking Abtect Phase 3 Data At 2025 UEG

    29 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/29/3158107/0/en/Abivax-Announces-Acceptance-of-Additional-Late-Breaking-Abstract-from-the-ABTECT-Phase-3-Induction-Trials-to-be-Presented-at-2025-United-European-Gastroenterology-UEG-Meeting.html

    GLOBENEWSWIRE
    29 Sep 2025
    Share Share
    Abivax Presents Obefazimod ABTECT Ph 3 Trials at 2025 UEG Meeting
    Abivax Presents Obefazimod ABTECT Ph 3 Trials at 2025 UEG Meeting

    23 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/23/3155082/0/en/Abivax-Announces-Presentation-of-Late-Breaking-Abstract-for-Obefazimod-from-the-ABTECT-Phase-3-Induction-Trials-at-2025-United-European-Gastroenterology-UEG-Meeting.html

    GLOBENEWSWIRE
    23 Sep 2025
    Share Share
    Abivax Reveals Ph3 Results for Obefazimod in Ulcerative Colitis
    Abivax Reveals Ph3 Results for Obefazimod in Ulcerative Colitis

    22 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/22/3119843/0/en/Abivax-Announces-Positive-Phase-3-Results-from-Both-ABTECT-8-Week-Induction-Trials-Investigating-Obefazimod-its-First-in-Class-Oral-miR-124-Enhancer-in-Moderate-to-Severely-Active-.html

    GLOBENEWSWIRE
    22 Jul 2025
    Share Share
    Abivax Presents 7 Abstracts On Obefazimod In Ulcerative Colitis
    Abivax Presents 7 Abstracts On Obefazimod In Ulcerative Colitis

    23 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/23/3014599/0/en/Abivax-Announces-Presentation-of-Seven-Abstracts-for-Obefazimod-in-Ulcerative-Colitis-at-2025-European-Crohn-s-and-Colitis-Organization-20th-Annual-Congress.html

    GLOBENEWSWIRE
    23 Jan 2025
    Share Share
    Abivax Enrolls 1st Patient In ENHANCE-CD Trial For Crohn's Disease
    Abivax Enrolls 1st Patient In ENHANCE-CD Trial For Crohn's Disease

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2958005/0/en/Abivax-Announces-First-Patient-Enrolled-in-ENHANCE-CD-the-Phase-2b-Trial-of-Obefazimod-in-Crohn-s-Disease.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    Abivax: 25mg Obefazimod Shows 2-Year Success In Colitis Study
    Abivax: 25mg Obefazimod Shows 2-Year Success In Colitis Study

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957449/0/en/Abivax-Reports-Positive-Interim-Efficacy-and-Safety-Analysis-of-Once-Daily-25mg-Obefazimod-in-Moderate-to-Severe-Ulcerative-Colitis-Patients-After-2-Years-of-Open-Label-Maintenance.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share